Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 8, 2004, Pages 2911-2917

  Hickman, Dean ^a   Vasavanonda, Sudthida ^a   Nequist, George ^a   Colletti, Lynn ^a   Kati, Warren M ^a   Bertz, Richard ^a   Hsu, Ann ^a   Kempf, Dale J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; TISSUE CULTURE MEDIUM;

ARTICLE; CULTURE MEDIUM; HUMAN IMMUNODEFICIENCY VIRUS; IC 50; MEASUREMENT; NONHUMAN; PLASMA; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VIRUS INHIBITION;

ALGORITHMS; ANIMALS; BIOLOGICAL ASSAY; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; KINETICS; PROTEIN BINDING; PYRIMIDINONES; RITONAVIR;

EID: 3342882525     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.8.2911-2917.2004     Document Type: Article

References (30)

1. Anderson, P. L., R. C. Brundage, L. Bushman, T. N. Kakuda, R. P. Remmel, and C. V. Fletcher. 2000. Indinavir plasma protein binding in HIV-1-infected adults. AIDS 14:2293-2297.
2. 50 ratio: call for consensus. J. Acquir. Immune Defic. Syndr. 27:210-211.
3. 1 acid glycoprotein. J. Infect. Dis. 171:546-551.
4. 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type-1 protease. Antimicrob. Agents Chemother. 40:1491-1497.
5. Bilello, J. A., and G. L. Drusano. 1996. Relevance of plasma protein binding to antiviral activity and clinical efficacy of inhibitors of human immunodeficiency virus protease. J. Infect. Dis. 173:1524-1525.
6. Condra, J. H., C. J. Petropoulos, R. Ziermann, W. A. Schleif, M. Shivaprakash, and E. A. Emini. 2000. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J. Infect. Dis. 182:758-765.
7. Drusano, G. L., J. A. Bilello, D. S. Stein, M. Nessly, A. Meibohm, E. A. Emini, P. Deutsch, J. Condra, J. Chodakewitz, and D. J. Holder. 1998. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic and pharmacologic variables. J. Infect. Dis. 178:360-367.
8. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
9. Finzi, D., M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, K. Chadwick, J. Margolick, R. Brookmeyer, J. Gallant, M. Markowitz, D. D. Ho, D. D. Richman, and R. F. Siliciano. 1997. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278:1295-1300.
10. Fischl, M. A., D. D. Richman, C. Flexner, M. F. Para, R. Haubrich, A. Karim, P. Yeramian, J. Holdenwiltse, and P. M. Meehan. 1997. Phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:28-34.
11. Gatti, G., E. Pontali, S. Boni, C. R. De Pascalis, M. Bassetti, and D. Bassetti. 2002. The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children. HIV Med. 3:125-128.
12. Gatti, G., A. Vigano, N. Sala, S. Vella, M. Bassetti, D. Bassetti, and N. Principi. 2000. Indinavir pharmacokinetics and pharmacodynamics in children with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 44:752-755.
13. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
14. Kays, M. B., R. L. White, G. Gatti, and J. G. Gambertoglio. 1992. Ex vivo protein binding of clindamycin in sera with normal and elevated alpha 1-acid glycoprotein concentrations. Pharmacotherapy 12:50-55.
15. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
16. Kempf, D. J., R. A. Rode, Y. Xu, E. Sun, M. E. Heath-Chiozzi, J. Valdes, A. J. Japour, S. Danner, C. Boucher, A. Molla, and J. M. Leonard. 1998. The duration of viral suppression during protease inhibitor therapy for HIV-1 infections is predicted by plasma HIV-1 RNA at the nadir. AIDS 12:F9-F14.
17. Lazdins, J. K., J. Mestan, G. Goutte, M. R. Walker, G. Bold, H. G. Capraro, and T. Klimkait. 1997. In vitro effect of α1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J. Infect. Dis. 175:1063-1070.
18. Matayoshi, E. D., G. T. Wang, G. A. Krafft, and J. Erickson. 1990. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 247:954-958.
19. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
20. Montaner, J., A. Hill, and E. Acosta. 2001. Practical implications for the interpretation of minimum plasma concentration/inhibitory concentration ratios. Lancet 357:1438-1440.
21. Morita, K., and A. Yamaji. 1995. Changes in the serum protein binding of vancomycin in patients with methicillin-resistant Staphylococcus aureus infection: the role of serum alpha 1-acid glycoprotein levels. Ther. Drug Monit. 17:107-112.
22. Morrison, J. F., and S. R. Stone. 1985. Approaches to the study and analysis of the inhibition of enzymes by slow- and tight-binding inhibitors. Mol. Cell. Biophys. 2:347-368.
23. Murphy, R. L., S. Brun, C. Hicks, J. T. Eron, R. Gulick, M. King, A. C. White, C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9.
24. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
25. Paxton, J. W., and R. H. Briant. 1984. Alpha 1-acid glycoprotein concentrations and propranolol binding in elderly patients with acute illness. Br. J. Clin. Pharmacol. 18:806-810.
26. Piliero, P. J. 2002. The utility of inhibitory quotients in determining the relative potency of protease inhibitors. AIDS 16:799-800.
27. Sadler, B. M., C. Gillotin, Y. Lou, and D. S. Stein. 2001. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing. Antimicrob. Agents Chemother. 45:30-37.
28. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C.-M. Chen, W. Kati, K. Stewart, R. Lai, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Nlu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. M. Leonard, J. J. Plattner, and D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
29. Shulman, N., A. Zolopa, D. Havlir, A. Hsu, C. Renz, S. Boller, P. Jiang, R. Rode, J. Gallant, E. Race, D. J. Kempf, and E. Sun. 2002. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother. 46:3907-3916.
30. Vanhove, G. F., J. M. Gries, D. Verotta, L. B. Sheiner, R. Coombs, A. C. Collier, and T. F. Blaschke. 1997. Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrob. Agents Chemother. 41:2433-2438.